DexCom has had quite a bumpy journey throughout the year. The Q4 report will be crucial in revealing full 2024 performance. The company has scheduled the fourth quarter and fiscal year 2024 earnings release and conference call for February 13, 2025. However, in Q3, Dexcom's (DXCM) decline was noted.
Positive news includes a new strategic partnership with ΕURA, with Dexcom pursuing a comeback with AI-driven glucose biosensing. However, news around insider selling, such as CEO Kevin R. Sayer selling 33,359 shares and various investment firms trimming or selling their Dexcom shares cast doubt. Concerns have been raised about slow revenue growth and disruptions to the sales force causing uncharacteristic earnings misses.
Despite this, others see reasons to buy, from solid shareholder returns over five years to Dexcom's ambitious 2025 growth targets. The launch of the first-ever Generative AI Platform in glucose biosensing signals innovation and potential growth for the future. DexCom stock was also upgraded to outperform by Baird. However, DexCom has been criticized and even accused of misleading investors, resulting in increased scrutiny.
Dexcom DXCM News Analytics from Mon, 17 Jun 2024 07:00:00 GMT to Sat, 01 Feb 2025 12:34:46 GMT - Rating -2 - Innovation 3 - Information 4 - Rumor -4
